Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses

Current Opinion in Structural Biology

Volumn 20, Issue 1, 2010, Pages 54-62

  Connelly, Stephen ^a   Choi, Sungwook ^a   Johnson, Steven M ^a   Kelly, Jeffery W ^a   Wilson, Ian A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PHENYLBENZOXAZOLE DERIVATIVE; AMYLOID; BENZOXAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; DIBENZOFURAN DERIVATIVE; PROTEIN INHIBITOR; THYROXINE; TRANSTHYRETIN KINETIC STABILIZER; UNCLASSIFIED DRUG;

AMYLOIDOSIS; BINDING SITE; CELL DEATH; COMPLEX FORMATION; DISSOCIATION; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HALOGENATION; HUMAN; LIGAND BINDING; MOLECULAR INTERACTION; NERVE DEGENERATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

AMYLOIDOSIS; ANIMALS; DRUG DESIGN; HUMANS; KINETICS; PREALBUMIN; PROTEIN STABILITY; THYROXINE;

EID: 77949272212     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sbi.2009.12.009     Document Type: Review

References (66)

1. Colon W., and Kelly J.W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31 (1992) 8654-8660
2. Kelly J.W., Colon W., Lai Z., Lashuel H.A., McCulloch J., McCutchen S.L., Miroy G.J., and Peterson S.A. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem 50 (1997) 161-181
3. Johnson S.M., Wiseman R.L., Sekijima Y., Green N.S., Adamski-Werner S.L., and Kelly J.W. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 38 (2005) 911-921. Review summarizing why ligand binding causes stabilization of the native state over the dissociative transition state raising the kinetic barrier for dissociation and, thus preventing amyloidogenesis.
4. Walsh D.M., and Selkoe D.J. Abeta oligomers-a decade of discovery. J Neurochem 101 (2007) 1172-1184
5. Lashuel H.A., Hartley D., Petre B.M., Walz T., and Lansbury Jr. P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418 (2002) 291
6. Pepys M.B. Amyloidosis. In: Little S.M. (Ed). Immunological Diseases vol. 1 (1988), Brown and Company 631-674
7. Cornwell G.C., Sletten K., Johansson B., and Westermark P. Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin. Biochem Biophys Res Commun 154 (1988) 648-653
8. Jacobson D.R., Pastore R.D., Yaghoubian R., Kane I., Gallo G., Buck F.S., and Buxbaum J.N. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336 (1997) 466-473
9. Hammarstrom P., Wiseman R.L., Powers E.T., and Kelly J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299 (2003) 713-716. A comparison of pharmacologic and genetic evidence demonstrating that kinetic stabilization of TTR should prevent amyloid disease. This manuscript describes a series of transthyretin amyloidosis inhibitors that functioned by increasing the kinetic barrier for dissociation. The trans-suppressor mutation, T119 M, which is known to ameliorate familial amyloid disease, was also shown to function through kinetic stabilization.
10. Coelho T., Carvalho M., Saraiva M.J., Alves I., Almeida M.R., and Costa P.P. A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR Met 30 and TTR Met 119. J Rheumatol 20 (1993) 179
11. Blake C.C., Geisow M.J., Oatley S.J., Rerat B., and Rerat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J Mol Biol 121 (1978) 339-356
12. Blake C.C., Geisow M.J., Swan I.D., Rerat C., and Rerat B. Structure of human plasma prealbumin at 2-5 Å resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J Mol Biol 88 (1974) 1-12
13. Hurshman Babbes A.R., Powers E.T., and Kelly J.W. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry 47 (2008) 6969-6984
14. Hornberg A., Eneqvist T., Olofsson A., Lundgren E., and Sauer-Eriksson A.E. A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J Mol Biol 302 (2000) 649-669. Structural comparisons of three wild-type, three non-amyloidogenic mutants, seven amyloidogenic mutants and nine complexes of TTR.
15. Sacchettini J.C., and Kelly J.W. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov 1 (2002) 267-275. A review of both small-molecule and macromolecular approaches for intervention in human amyloid diseases.
16. Wojtczak A., Cody V., Luft J.R., and Pangborn W. Structures of human transthyretin complexed with thyroxine at 2.0 Å resolution and 3′,5′-dinitro-N-acetyl-l-thyronine at 2.2 Å resolution. Acta Crystallogr D Biol Crystallogr 52 (1996) 758-765
17. Cody V. Mechanisms of molecular recognition: crystal structure analysis of human and rat transthyretin inhibitor complexes. Clin Chem Lab Med 40 (2002) 1237-1243
18. Johnson S.M., Petrassi H.M., Palaninathan S.K., Mohamedmohaideen N.N., Purkey H.E., Nichols C., Chiang K.P., Walkup T., Sacchettini J.C., Sharpless K.B., et al. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem 48 (2005) 1576-1587
19. Purkey H.E., Palaninathan S.K., Kent K.C., Smith C., Safe S.H., Sacchettini J.C., and Kelly J.W. Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem Biol 11 (2004) 1719-1728
20. Razavi H., Palaninathan S.K., Powers E.T., Wiseman R.L., Purkey H.E., Mohamedmohaideen N.N., Deechongkit S., Chiang K.P., Dendle M.T., Sacchettini J.C., et al. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Engl 42 (2003) 2758-2761
21. Adamski-Werner S.L., Palaninathan S.K., Sacchettini J.C., and Kelly J.W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 47 (2004) 355-374
22. Klabunde T., Petrassi H.M., Oza V.B., Raman P., Kelly J.W., and Sacchettini J.C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 7 (2000) 312-321
23. Oza V.B., Petrassi H.M., Purkey H.E., and Kelly J.W. Synthesis and evaluation of biaryl amines and benzylamines as inhibitors of TTR amyloid fibril formation. Book of Abstracts, 217th ACS National Meeting. Anaheim, California (1999) ORGN-447
24. Oza V.B., Petrassi H.M., Purkey H.E., and Kelly J.W. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg Med Chem Lett 9 (1999) 1-6
25. Oza V.B., Smith C., Raman P., Koepf E.K., Lashuel H.A., Petrassi H.M., Chiang K.P., Powers E.T., Sachettinni J., and Kelly J.W. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem 45 (2002) 321-332
26. Johnson S.M., Connelly S., Wilson I.A., and Kelly J.W. Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem 51 (2008) 6348-6358. The first of three studies aimed at systematically optimizing the three substructures comprising typical TTR kinetic stabilizers, the two aryl rings and the linker joining them. This paper outlines biochemical and structural data on a library of 2-arylbenzoxazoles bearing thyroid hormone-like aryl substituents on the 2-aryl ring to optimize the aryl-X substructure.
27. Johnson S.M., Connelly S., Wilson I.A., and Kelly J.W. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J Med Chem 51 (2008) 260-270. The second of three studies optimizing the linker substructure comprising typical TTR kinetic stabilizers, whereby 40 molecules composed of 10 unique linker substructures were evaluated both biochemically and structurally to determine how these linkages influence inhibitor potency and selectivity.
28. Johnson S.M., Connelly S., Wilson I.A., and Kelly J.W. Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis. Inhibitors using biochemical and structural studies. J Med Chem 52 (2009) 1115-1125. The last paper of a 3-part series focused on optimizing the second aryl ring of a typical TTR kinetic stabilizer. Both biochemical and structural evaluation of a library of compounds employing a suboptimal linker and an optimal aryl-X was utilized to rank order the aryl-Z substructures.
29. Petrassi H.M., Johnson S.M., Purkey H.E., Chiang K.P., Walkup T., Jiang X., Powers E.T., and Kelly J.W. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. J Am Chem Soc 127 (2005) 6662-6671
30. Petrassi H.M., Klabunde T., Sacchettini J., and Kelly J.W. Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J Am Chem Soc 122 (2000) 2178-2192
31. Wojtczak A., Luft J., and Cody V. Mechanism of molecular recognition. Structural aspects of 3,3′-diiodo-l-thyroxine binding to human serum transthyretin. J Biol Chem 267 (1992) 353-357
32. Ciszak E., Cody V., and Luft J.R. Crystal structure determination at 2.3 Å resolution of human transthyretin-3′,5′-dibromo-2′,4,4′,6-tetrahydroxyaurone complex. Proc Natl Acad Sci 89 (1992) 6644-6648
33. Hamilton J.A., Steinrauf L.K., Braden B.C., Liepnieks J., Benson M.D., Holmgren G., Sandgren O., and Steen L. The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30 to Met variant to 1.7-Å resolution. J Biol Chem 268 (1993) 2416-2424
34. Wojtczak A., Luft J.R., and Cody V. Structural aspects of inotropic bipyridine binding. Crystal structure determination to 1. 9 Å of the serum transthyretin-milrinone complex. J Biol Chem 268 (1993) 6202-6206
35. Monaco H.L., Rizzi M., and Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 268 (1995) 1039-1041
36. Zanotti G., D'Acunto M.R., Malpeli G., Folli C., and Berni R. Crystal structure of the transthyretin-retinoic-acid complex. Eur J Biochem 234 (1995) 563-569
37. Sunde M., Richardson S.J., Chang L., Pettersson T.M., Schreiber G., and Blake C.C. The crystal structure of transthyretin from chicken. Eur J Biochem 236 (1996) 491-499
38. Peterson S.A., Klabunde T., Lashuel H., Purkey H., Sacchettini J.C., and Kelly J.W. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci U S A 95 (1998) 12956-12960
39. Naylor H.M., and Newcomer M.E. The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. Biochemistry 38 (1999) 2647-2653
40. Sebastiao M.P., Merlini G., Saraiva M.J., and Damas A.M. The molecular interaction of 4′-iodo-4′-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation. Biochem J 351 (2000) 273-279
41. Wojtczak A., Cody V., Luft J.R., and Pangborn W. Structure of rat transthyretin (rTTR) complex with thyroxine at 2.5 A resolution: first non-biased insight into thyroxine binding reveals different hormone orientation in two binding sites. Acta Crystallogr D Biol Crystallogr 57 (2001) 1061-1070
42. 4-bound tetramers of TTR. Acta Crystallogr D Biol Crystallogr 57 (2001) 957-967
43. Muziol T., Cody V., and Wojtczak A. Comparison of binding interactions of dibromoflavonoids with transthyretin. Acta Biochim Pol 48 (2001) 885-892
44. Eneqvist T., Lundberg E., Karlsson A., Huang S., Santos C.R., Power D.M., and Sauer-Eriksson A.E. High resolution crystal structures of piscine transthyretin reveal different binding modes for triiodothyronine and thyroxine. J Biol Chem 279 (2004) 26411-26416
45. Morais-de-Sa E., Pereira P.J., Saraiva M.J., and Damas A.M. The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors. J Biol Chem 279 (2004) 53483-53490
46. Neto-Silva R.M., Macedo-Ribeiro S., Pereira P.J., Coll M., Saraiva M.J., and Damas A.M. X-ray crystallographic studies of two transthyretin variants: further insights into amyloidogenesis. Acta Crystallogr D Biol Crystallogr 61 (2005) 333-339
47. Wiseman R.L., Johnson S.M., Kelker M.S., Foss T., Wilson I.A., and Kelly J.W. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J Am Chem Soc 127 (2005) 5540-5551
48. Gales L., Macedo-Ribeiro S., Arsequell G., Valencia G., Saraiva M.J., and Damas A.M. Human transthyretin in complex with iododiflunisal-structural features associated with a potent amyloid inhibitor. Biochem J 388 (2005) 615-621
49. 4Ac complex at 2.2 Å resolution. Acta Crystallogr D Biol Crystallogr 61 (2005) 1313-1319
50. Morais-de-Sa E., Neto-Silva R.M., Pereira P.J., Saraiva M.J., and Damas A.M. The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin. Acta Crystallogr D Biol Crystallogr 62 (2006) 512-519
51. Razavi H., Powers E.T., Purkey H.E., Adamski-Werner S.L., Chiang K.P., Dendle M.T., and Kelly J.W. Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors. Bioorg Med Chem Lett 15 (2005) 1075-1078
52. Gales L., Almeida M.R., Arsequell G., Valencia G., Saraiva M.J., and Damas A.M. Iodination of salicylic acid improves its binding to transthyretin. Biochim Biophys Acta, Proteins Proteomics 1784 (2008) 512-517
53. Mairal T., Nieto J., Pinto M., Almeida M.R., Gales L., Ballesteros A., Barluenga J., Perez J.J., Vazquez J.T., Centeno N.B., et al. Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS One 4 (2009) e4124
54. Palaninathan S.K., Mohamedmohaideen N.N., Orlandini E., Ortore G., Nencetti S., Lapucci A., Rossello A., Freundlich J.S., and Sacchettini J.C. Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis. PLoS One 4 (2009) e6290
55. Epstein M. Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction. J Hypertens Suppl 20 (2002) S17-23
56. Baures P.W., Peterson S.A., and Kelly J.W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem 6 (1998) 1389-1401
57. 4, and decreases serum Thyrotropin in the rat. Endocrinology 126 (1990) 2890-2895
58. Maia F., Almeida Mdo R., Gales L., Kijjoa A., Pinto M.M., Saraiva M.J., and Damas A.M. The binding of xanthone derivatives to transthyretin. Biochem Pharmacol 70 (2005) 1861-1869
59. Almeida M.R., Macedo B., Cardoso I., Alves I., Valencia G., Arsequell G., Planas A., and Saraiva M.J. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J 381 (2004) 351-356
60. Miller S.R., Sekijima Y., and Kelly J.W. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 84 (2004) 545-552
61. Dolado I., Nieto J., Saraiva M.J., Arsequell G., Valencia G., and Planas A. Kinetic assay for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors. J Comb Chem 7 (2005) 246-252
62. Baures P.W., Oza V.B., Peterson S.A., and Kelly J.W. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the nonsteroidal antiinflammatory drug flufenamic acid. Bioorg Med Chem 7 (1999) 1339-1347
63. Gonzalez A., Quirante J., Nieto J., Almeida M.R., Saraiva M.J., Planas A., Arsequell G., and Valencia G. Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors. Bioorg Med Chem Lett 19 (2009) 5270-5273
64. ••] on optimized substructures to generate a library of potent and selective TTR kinetic stabilizers.
65. Andrea T.A., Cavalieri R.R., Goldfine I.D., and Jorgensen E.C. Binding of thyroid hormones and analogs to the human plasma protein prealbumin. Biochemistry 19 (1980) 55-63
66. Auffinger P., Hays F.A., Westhof E., and Ho P.S. Halogen bonds in biological molecules. Proc Natl Acad Sci USA 101 (2004) 16789-16794